EcoDrugPlus

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSONIG00000002723
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSONIG00000008418
Gene Symbol: HCN4
1 Cross references
212 Possible Orthologues:

Hypocretin Receptor 2

Ensembl ID : ENSONIG00000009721
Gene Symbol: HCRTR2
3 Cross references
203 Possible Orthologues:

Ileal Sodium/bile Acid Cotransporter

Ensembl ID : ENSONIG00000028469
Gene Symbol: LOC100693964
3 Cross references
214 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta

Ensembl ID : ENSONIG00000014360
Gene Symbol: IKBKB
4 Cross references
199 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSONIG00000001696
Gene Symbol: IMPDH2
4 Cross references
200 Possible Orthologues:

Inosine-5'-Monophosphate Dehydrogenase 1a

Ensembl ID : ENSONIG00000014917
Gene Symbol: LOC100701529
3 Cross references
258 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSONIG00000019319
Gene Symbol: INPP5D
4 Cross references
215 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSONIG00000018609
Gene Symbol: LOC100696191
3 Cross references
212 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSONIG00000001811
Gene Symbol: LOC100697854
4 Cross references
212 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSONIG00000015115
Gene Symbol: LOC100711993
4 Cross references
204 Possible Orthologues:

Insulin-Like Growth Factor 1 Receptor

Ensembl ID : ENSONIG00000002961
Gene Symbol: LOC100707581
4 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).